Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 4739

1.

Delay aversion and Executive Functioning in adults with Attention-Deficit/Hyperactivity Disorder: Before and after stimulant treatment.

Low AM, le Sommer J, Vangkilde S, Fagerlund B, Glenthøj B, Sonuga-Barke E, Habekost T, Jepsen JRM.

Int J Neuropsychopharmacol. 2018 Aug 16. doi: 10.1093/ijnp/pyy070. [Epub ahead of print]

PMID:
30124878
2.

Are the effects of methylphenidate uncertain?

Cortese S.

Ir J Psychol Med. 2018 Sep;35(3):163-167. doi: 10.1017/ipm.2018.16.

PMID:
30124188
3.

[Supervised off-label prescribing of methylphenidate in adult ADHD].

Carton L, Dondaine T, Deheul S, Marquié C, Brigadeau F, Amad A, Devos D, Danel T, Bordet R, Cottencin O, Gautier S, Ménard O.

Encephale. 2018 Aug 16. pii: S0013-7006(18)30092-7. doi: 10.1016/j.encep.2018.05.008. [Epub ahead of print] French.

PMID:
30122296
4.

Population Pharmacokinetic-Pharmacodynamic Modeling of a Novel Methylphenidate Extended-Release Orally Disintegrating Tablet in Pediatric Patients With Attention-Deficit/Hyperactivity Disorder.

Teuscher NS, Sikes CR, McMahen R, Engelking D.

J Clin Psychopharmacol. 2018 Aug 16. doi: 10.1097/JCP.0000000000000944. [Epub ahead of print]

PMID:
30119076
5.
6.

Incidence of Heart Failure and Cardiomyopathy Following Initiation of Medications for Attention-Deficit/Hyperactivity Disorder: A Descriptive Study.

Mosholder AD, Taylor L, Mannheim G, Ortendahl L, Woodworth TS, Toh S.

J Clin Psychopharmacol. 2018 Aug 10. doi: 10.1097/JCP.0000000000000939. [Epub ahead of print]

PMID:
30102629
7.

Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis.

Cortese S, Adamo N, Del Giovane C, Mohr-Jensen C, Hayes AJ, Carucci S, Atkinson LZ, Tessari L, Banaschewski T, Coghill D, Hollis C, Simonoff E, Zuddas A, Barbui C, Purgato M, Steinhausen HC, Shokraneh F, Xia J, Cipriani A.

Lancet Psychiatry. 2018 Aug 7. pii: S2215-0366(18)30269-4. doi: 10.1016/S2215-0366(18)30269-4. [Epub ahead of print]

8.

Nonmedical Use of Stimulants Is Associated With Riskier Sexual Practices and Other Forms of Impulsivity.

Grant JE, Redden SA, Lust K, Chamberlain SR.

J Addict Med. 2018 Aug 7. doi: 10.1097/ADM.0000000000000448. [Epub ahead of print]

PMID:
30095567
9.

Alopecia Associated with Use of Methylphenidate: A Case Series.

Gnanavel S, Hussain S.

Indian J Psychol Med. 2018 Jul-Aug;40(4):370-371. doi: 10.4103/IJPSYM.IJPSYM_63_18.

10.

Management of Attention Deficit Hyperactivity Disorder During Pregnancy.

Baker AS, Freeman MP.

Obstet Gynecol Clin North Am. 2018 Sep;45(3):495-509. doi: 10.1016/j.ogc.2018.04.010. Review.

PMID:
30092924
11.

Long-term use of methylphenidate in a boy with hypothalamic tumor, drug-resistant epilepsy and ADHD.

Socanski D, Jovic N, Beneventi H, Herigstad A.

Epilepsy Behav Case Rep. 2018 Apr 20;10:82-85. doi: 10.1016/j.ebcr.2018.03.002. eCollection 2018.

12.

Relationship Between Aggravation of Seizures and Methylphenidate Treatment in Subjects with Attention-Deficit/Hyperactivity Disorder and Epilepsy.

Park J, Choi HW, Yum MS, Ko TS, Shon SH, Kim HW.

J Child Adolesc Psychopharmacol. 2018 Aug 8. doi: 10.1089/cap.2017.0070. [Epub ahead of print]

PMID:
30089215
13.

ADHD: methylphenidate should be first line drug treatment in children, review confirms.

Iacobucci G.

BMJ. 2018 Aug 7;362:k3430. doi: 10.1136/bmj.k3430. No abstract available.

PMID:
30087150
14.

A multicentre randomized controlled trial on trans-generational attention deficit/hyperactivity disorder (ADHD) in mothers and children (AIMAC): an exploratory analysis of predictors and moderators of treatment outcome.

Jaite C, van Noort BM, Vloet TD, Graf E, Kappel V, Geissler J, Warnke A, Jacob C, Groß-Lesch S, Hennighausen K, Haack-Dees B, Schneider-Momm K, Philipsen A, Matthies S, Rösler M, Retz W, Hänig S, von Gontard A, Sobanski E, Alm B, Hohmann S, Häge A, Poustka L, Colla M, Gentschow L, Freitag CM, Becker K, Jans T.

Z Kinder Jugendpsychiatr Psychother. 2018 Aug 7:1-17. doi: 10.1024/1422-4917/a000602. [Epub ahead of print]

15.

Risk-of-Bias and Quality-of-Evidence for Treatment of ADHD with Stimulant Medication.

Swanson JM.

Clin Pharmacol Ther. 2018 Jul 31. doi: 10.1002/cpt.1186. [Epub ahead of print] Review.

PMID:
30066372
16.

Using ADHD Medications to Treat Coexisting ADHD and Reading Disorders: A Systematic Review.

Froehlich T, Fogler J, Barbaresi WJ, Elsayed NA, Evans SW, Chan E.

Clin Pharmacol Ther. 2018 Jul 27. doi: 10.1002/cpt.1192. [Epub ahead of print] Review.

PMID:
30053315
17.

DRD3 Gene and ADHD: A Pharmaco-Behavioural Genetic Study.

Fageera W, Sengupta SM, Labbe A, Grizenko N, Joober R.

Neuromolecular Med. 2018 Jul 26. doi: 10.1007/s12017-018-8504-z. [Epub ahead of print]

PMID:
30051166
18.

Relationship Between Symptomatic and Functional Improvement and Remission in a Treatment Response to Stimulant Trial.

Weiss M, Childress A, Mattingly G, Nordbrock E, Kupper RJ, Adjei AL.

J Child Adolesc Psychopharmacol. 2018 Jul 23. doi: 10.1089/cap.2017.0166. [Epub ahead of print]

PMID:
30036076
19.

Methylation of the dopamine transporter gene in blood is associated with striatal dopamine transporter availability in ADHD: a preliminary study.

Wiers CE, Lohoff FW, Lee J, Muench C, Freeman C, Zehra A, Marenco S, Lipska BK, Auluck PK, Feng N, Sun H, Goldman D, Swanson JM, Wang GJ, Volkow ND.

Eur J Neurosci. 2018 Jul 23. doi: 10.1111/ejn.14067. [Epub ahead of print]

PMID:
30033547
20.

Recovery from behavior and developmental effects of chronic oral methylphenidate following an abstinence period.

Martin C, Fricke D, Vijayashanthar A, Lowinger C, Koutsomitis D, Popoola D, Hadjiargyrou M, Komatsu DE, Thanos PK.

Pharmacol Biochem Behav. 2018 Sep;172:22-32. doi: 10.1016/j.pbb.2018.07.001. Epub 2018 Jul 18.

PMID:
30030127

Supplemental Content

Loading ...
Support Center